Production and crystallization of recombinant JAK proteins

Methods in Molecular Biology

Volumn 967, Issue , 2013, Pages 275-300

  Lucet, Isabelle S ^a   Bamert, Rebecca ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Baculovirus expression; Crystallization; JAK kinase domain; JAK kinases; Phosphorylation; Protein puri fication

Indexed keywords

JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; PROTEIN KINASE TYK2; RECOMBINANT PROTEIN; JANUS KINASE; PROTEIN KINASE INHIBITOR;

ANIMAL CELL; CRYSTAL STRUCTURE; CRYSTALLIZATION; ENZYME PHOSPHORYLATION; ENZYME STRUCTURE; FEMALE; NONHUMAN; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SF9 CELL LINE; VIRUS RECOMBINANT; ANIMAL; ARTICLE; BIOSYNTHESIS; CHEMISTRY; GENETIC ENGINEERING; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; METHODOLOGY; MOLECULAR CLONING; PHOSPHORYLATION; PROTEIN TERTIARY STRUCTURE; SF9 CELL; SPODOPTERA;

ANIMALS; CLONING, MOLECULAR; CRYSTALLIZATION; GENETIC ENGINEERING; HUMANS; JANUS KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; SF9 CELLS; SPODOPTERA;

EID: 84878764309     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-242-1_20     Document Type: Chapter

References (27)

1. Wilks AF (2008) The JAK kinases: not just another kinase drug discovery target. Semin Cell Dev Biol 19:319–328.
2. Harpur AG, Andres AC, Ziemiecki A et al (1992) JAK2, a third member of the JAK family of protein tyrosine kinases. Oncogene 7:1347–1353.
3. Chrencik JE, Patny A, Leung IK et al (2010) Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6. J Mol Biol 400:413–433.
4. Tsui V, Gibbons P, Ultsch M et al (2011) A new regulatory switch in a JAK protein kinase. Proteins 79:393–401.
5. Liu Y, Gray NS (2006) Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2:358–364.
6. Haan C, Kroy DC, Wuller S et al (2009) An unusual insertion in Jak2 is crucial for kinase activity and differentially affects cytokine responses. J Immunol 182:2969–2977.
7. Lucet IS, Fantino E, Styles M et al (2006) The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood 107:176–183.
8. Alicea-Velazquez NL, Boggon TJ (2011) The use of structural biology in Janus kinase targeted drug discovery. Curr Drug Targets 12:546–555
9. Ioannidis S, Lamb ML, Wang T et al (2011) Discovery of 5-Chloro-N(2)-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N(4)-(5-methyl-1H-pyr azol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a Novel Inhibitor of the Jak/ Stat Pathway. J Med Chem 54:262–276.
10. Korniski B, Wittwer AJ, Emmons TL et al (2010) Expression, puri fication, and characterization of TYK-2 kinase domain, a member of the Janus kinase family. Biochem Biophys Res Commun 396:543–548.
11. Hall T, Emmons TL, Chrencik JE et al (2010) Expression, purification, characterization and crystallization of non- and phosphorylated states of JAK2 and JAK3 kinase domain. Protein Expr Purif 69:54–63.
12. Boggon TJ, Li Y, Manley PW et al (2005) Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. Blood 106:996–1002.
13. Williams NK, Bamert RS, Patel O et al (2009) Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. J Mol Biol 387:219–232.
14. Wang T, Duffy JP, Wang J et al (2009) Janus kinase 2 inhibitors. Synthesis and characterization of a novel polycyclic azaindole. J Med Chem 52:7938–7941.
15. Thompson JE, Cubbon RM, Cummings RT et al (2002) Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. Bioorg Med Chem Lett 12:1219–1223.
16. Changelian PS, Flanagan ME, Ball DJ et al (2003) Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302:875–878.
17. Chayen NE, Saridakis E (2008) Protein crystallization: from purified protein to diffractionquality crystal. Nat Methods 5:147–153.
18. McPherson A (1999) Crystallization of biological macromolecules. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
19. Wang T, Ioannidis S, Almeida L et al (2011) In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors. Bioorg Med Chem Lett 21: 2958–2961.
20. Wang T, Ledeboer MW, Duffy JP et al (2010) A novel chemotype of kinase inhibitors: discovery of 3,4-ring fused 7-azaindoles and deazapurines as potent JAK2 inhibitors. Bioorg Med Chem Lett 20:153–156.
21. Bergfors T (2003) Seeds to crystals. J Struct Biol 142:66–76.
22. King LA, Hitchman R, Possee RD (2007) Recombinant baculovirus isolation. Methods Mol Biol 388:77–94.
23. Antonysamy S, Hirst G, Park F et al (2009) Fragment-based discovery of JAK-2 inhibitors. Bioorg Med Chem Lett 19:279–282.
24. Baffert F, Regnier CH, De Pover A et al (2010) Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805. Mol Cancer Ther 9: 1945–1955.
25. Pissot-Soldermann C, Gerspacher M, Furet P et al (2010) Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitors. Bioorg Med Chem Lett 20:2609–2613.
26. Harikrishnan LS, Kamau MG, Wan H et al (2011) Pyrrolo[1,2-f]triazines as JAK2 inhibitors: achieving potency and selectivity for JAK2 over JAK3. Bioorg Med Chem Lett 21: 1425–1428.
27. Thoma G, Nuninger F, Falchetto R et al (2011) Identification of a potent Janus Kinase 3 inhibitor with high selectivity within the Janus Kinase family. J Med Chem 54: 284–288.